Abstract
Transitional metals have a large variety of coordination numbers and geometries, accessible redox states in physiological conditions and a wide range of thermodynamic and reactivity properties which can be successfully tuned by selection of suitable ligands. These characteristics can be used to develop new drugs with numerous advantages over the organic based drugs. Historically, research in this field has focus on platinum and DNA targeting; however, anticancer drug research may be expanded to include alternative metal compounds with different mode of action resulting in markedly different cytotoxic response profiles. Copper complexes with selected ligands are being extensively studied as agents for the treatment of cancer. Current research on copper compounds as antitumoral compounds is being reviewed in this chapter particularly focused on the family of copper Casiopeinas.
Keywords: Copper compounds, drugs, medicinal inorganic chemistry, Cancer Chemotherapy, organic based drugs, geometries, DNA targeting, copper Casiopeinas, low hydrosolubility, cisplatin (CDDP), therapeutic potential, tumor cell growth, cell proliferation, antitumor agents, Casiopeínas®, Pt clinical drugs, Carboplatino, Oxalilplatino, Nedaplatino, Lobaplatino, Cu (II) thiosemicarbazidecomplexes, Isatin-Schiff base copper (II), platinum-based drugs, ascorbate oxidase, tyrosinase, copper-biological molecules, Wilson disease (WD), Menkes disease (MD), thiosemicarbazone complexes, imidazole, benzimidazole, phenanthroline, bipyridine complexes, antiproliferative activity, Casiopeína II-gly, Casiopeína III-ia, phenanthrolines, L-amino acidate, mixed-ligand complexes, phenanthroline basicity, Structure-Activity Relationships, cytostatic, genotoxic, antitumor activi-ties, diimine ligand, murine glioma, genotoxic activity, Melanoma B16, Leukemia L1210, medulloblastoma, glutathione depletion, hemolytic anemia, Cytotoxicity, hematological effects, cardiovascular toxicity, antineoplastic drug, cisplatin therapy, copper-based antitumor agents, metal, –, ligand combination, recognition of target sites
Current Medicinal Chemistry
Title: Copper Compounds in Cancer Chemotherapy
Volume: 17 Issue: 31
Author(s): L. Ruiz-Azuara and M. E. Bravo-Gomez
Affiliation:
Keywords: Copper compounds, drugs, medicinal inorganic chemistry, Cancer Chemotherapy, organic based drugs, geometries, DNA targeting, copper Casiopeinas, low hydrosolubility, cisplatin (CDDP), therapeutic potential, tumor cell growth, cell proliferation, antitumor agents, Casiopeínas®, Pt clinical drugs, Carboplatino, Oxalilplatino, Nedaplatino, Lobaplatino, Cu (II) thiosemicarbazidecomplexes, Isatin-Schiff base copper (II), platinum-based drugs, ascorbate oxidase, tyrosinase, copper-biological molecules, Wilson disease (WD), Menkes disease (MD), thiosemicarbazone complexes, imidazole, benzimidazole, phenanthroline, bipyridine complexes, antiproliferative activity, Casiopeína II-gly, Casiopeína III-ia, phenanthrolines, L-amino acidate, mixed-ligand complexes, phenanthroline basicity, Structure-Activity Relationships, cytostatic, genotoxic, antitumor activi-ties, diimine ligand, murine glioma, genotoxic activity, Melanoma B16, Leukemia L1210, medulloblastoma, glutathione depletion, hemolytic anemia, Cytotoxicity, hematological effects, cardiovascular toxicity, antineoplastic drug, cisplatin therapy, copper-based antitumor agents, metal, –, ligand combination, recognition of target sites
Abstract: Transitional metals have a large variety of coordination numbers and geometries, accessible redox states in physiological conditions and a wide range of thermodynamic and reactivity properties which can be successfully tuned by selection of suitable ligands. These characteristics can be used to develop new drugs with numerous advantages over the organic based drugs. Historically, research in this field has focus on platinum and DNA targeting; however, anticancer drug research may be expanded to include alternative metal compounds with different mode of action resulting in markedly different cytotoxic response profiles. Copper complexes with selected ligands are being extensively studied as agents for the treatment of cancer. Current research on copper compounds as antitumoral compounds is being reviewed in this chapter particularly focused on the family of copper Casiopeinas.
Export Options
About this article
Cite this article as:
Ruiz-Azuara L. and E. Bravo-Gomez M., Copper Compounds in Cancer Chemotherapy, Current Medicinal Chemistry 2010; 17 (31) . https://dx.doi.org/10.2174/092986710793213751
DOI https://dx.doi.org/10.2174/092986710793213751 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Editorial: Smart Drug Delivery Systems (Part 1)
Current Drug Targets Gallium-68: A New Trend in PET Radiopharmacy
Current Radiopharmaceuticals Endothelin-1 and Angiogenesis in Cancer
Current Vascular Pharmacology Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment
Current Drug Targets Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Nitric Oxide is a Key Molecule Serving as a Bridge between Radiation-Induced Bystander and Adaptive Responses
Current Molecular Pharmacology